Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy.
about
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance.Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats.Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infectionFracture incidence in HIV-infected women: results from the Women's Interagency HIV Study.Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based PerspectiveCharacteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosisHIV and bone metabolismFracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system.The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis.Use of dual-energy x-ray absorptiometry (DXA) scans in HIV-infected patients.Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.Alendronate treatment for osteoporosis in patients infected with human immunodeficiency virus.Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta).Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France.The Aging Skeleton: Differences Between HIV-Infected Patients and the Uninfected Aging Population
P2860
Q33844059-94B86F29-88E7-43BF-89F6-4889F6CE0CDAQ34068440-4CCA995B-8764-4DB3-9298-CAE97A9B4912Q34506677-C25357D9-CA7C-45BE-9E4F-F2C323F3A3E9Q35024409-9E541F84-04CA-4625-AFE0-DF7D83E640E1Q35025528-362808F5-6064-4DAB-9E24-D6974614DAEDQ35557338-623DE0B9-E541-4603-9021-7185EFC7A3D4Q36337716-7429DA74-7F3B-42A8-95F0-9599D3666894Q36671233-7E72D661-5F7F-43ED-87F9-B66BE8EF6B84Q36938343-1A496B71-9F31-4BBA-8468-6DA2D20D2A61Q37287589-B0AF968F-FD36-4F81-8744-CAA9C6E0D5C7Q38003367-D8C02A6C-17E1-4A6C-B6A2-BB5A37B72E80Q39010553-5F61F510-926D-46A5-9048-938D14C43BC0Q43663027-53D70825-11DC-4579-AC13-D9B21B26732CQ44242461-66A3D499-B8C9-43F7-840F-2662D849A08EQ45161674-CD6D5BCC-471A-42BA-9970-6431FA2AC7E1Q46200243-1D3341D0-86D8-4710-982F-0AFB10ADDDD3Q58797971-13F399B6-46D5-4A4B-B1DF-DC52263EE215
P2860
Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Pathological fractures in AIDS ...... ced by antiretroviral therapy.
@en
Pathological fractures in AIDS ...... ced by antiretroviral therapy.
@nl
type
label
Pathological fractures in AIDS ...... ced by antiretroviral therapy.
@en
Pathological fractures in AIDS ...... ced by antiretroviral therapy.
@nl
prefLabel
Pathological fractures in AIDS ...... ced by antiretroviral therapy.
@en
Pathological fractures in AIDS ...... ced by antiretroviral therapy.
@nl
P2093
P921
P1433
P1476
Pathological fractures in AIDS ...... ced by antiretroviral therapy.
@en
P2093
P304
P356
10.1097/00002030-200101050-00025
P407
P577
2001-01-01T00:00:00Z